Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + venetoclax for myeloproliferative chronic myelomonocytic leukemia
ChiCTR2400079363Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine and venetoclax in chronic myelomonocytic leukemia (CMML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall response rate, Complete response / equivalent complete response and 4 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
decitabinevenetoclax
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ChiCTR2400079363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079363.